Selective mAChR M4 Antagonists for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as levodopa and muscarinic acetylcholine receptor antagonists, face limitations due to adverse effects and lack of selectivity, which restricts their efficacy and clinical utility, particularly in achieving complete blockade of specific muscarinic acetylcholine receptor subtypes responsible for antiparkinsonian effects.
Innovation Solution
Development of compounds, specifically substituted hexahydro-1H-cyclopenta[c]pyrrole derivatives, that act as selective antagonists of the muscarinic acetylcholine receptor M4 subtype, offering a more targeted approach to treating Parkinson's disease and related disorders by antagonizing mAChR M4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective mAChR antagonists (e.g., scopolamine) are used to treat Parkinson's disease, then antiparkinsonian effects are achieved through blockade of mAChR subtypes, but dose-limiting adverse effects occur due to blockade of mAChR subtypes not involved in antiparkinsonian activity
Solution Approach 1:
The invention segments the mAChR antagonism into subtype-specific blockade. Instead of using nonselective antagonists that block all mAChR subtypes (M1-M5), the patent develops compounds that selectively block only the M4 subtype, which is responsible for antiparkinsonian effects. This segmentation allows therapeutic action to be isolated to the beneficial pathway while sparing other subtypes from causing adverse effects.
Solution Approach 2:
The invention applies local quality by creating antagonists with specific affinity for the M4 mAChR subtype. The compounds are designed to interact preferentially with the M4 receptor structure, providing localized pharmacological action at the M4 subtype while leaving M1, M2, M3, and M5 subtypes unaffected. This selective interaction resolves the contradiction by concentrating therapeutic effects where needed while avoiding harmful blockade elsewhere.
2Reliability
If doses of nonselective mAChR antagonists are increased to achieve more complete blockade, then antiparkinsonian efficacy may be improved, but adverse effects are exacerbated
Solution Approach 1:
The segmentation principle allows achieving complete M4 subtype blockade without proportionally increasing blockade of other subtypes. By designing selective M4 antagonists, the patent enables dosing that fully blocks the therapeutic target (M4) while maintaining safety, as other mAChR subtypes remain functionally intact. This resolves the dose-limiting problem inherent with nonselective antagonists.
Solution Approach 2:
The invention changes the selectivity parameter of the antagonist compounds. Instead of using compounds with broad-spectrum mAChR blockade, the patent develops agents with high selectivity for M4 subtype. This parameter change in receptor specificity allows the therapeutic window to be expanded, enabling effective doses that achieve complete M4 blockade without reaching toxic thresholds for other subtypes.
3Object-affected harmful factors
If selective M4 mAChR antagonists are developed, then adverse effects are reduced through sparing of other mAChR subtypes, but compound selectivity and specificity must be optimized
Solution Approach 1:
The invention achieves local quality by designing molecules with specific structural features that confer selectivity for M4 mAChR. The compounds contain pharmacophoric elements that match the binding pocket characteristics of M4 receptor, allowing preferential interaction with this subtype. This molecular-level local quality ensures that therapeutic action is directed specifically at M4 while other subtypes are spared, resolving the selectivity challenge.
Solution Approach 2:
The patent optimizes the selectivity parameter through systematic modification of compound structure. By adjusting molecular properties such as steric bulk, electronic distribution, and hydrogen bonding capacity, the invention fine-tunes affinity for M4 versus other mAChR subtypes. This parameter optimization ensures high selectivity ratios, achieving the desired balance between adverse effect reduction and manufacturing precision.
Data Source
AI summary
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.